Subtype
Malignant Urinary Tract Neoplasm
CI-CAN-00003252Explore in graph →
507 active trials14 approved drugs29 evidence items
- NCIt
- C192668
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003252Explore in graph →
Clinical trials
1,955 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (246)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06405425 | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | recruiting | Phase 2 | 52 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07721935 | Development of an AI-Agent for Urological Disease Diagnosis and Treatment | recruiting | — | 2,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 23, 2026 |
| clinicaltrials |
| NCT04879329 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | recruiting | Phase 2 | 372 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 12 | Jul 22, 2026 | clinicaltrials |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | active not recruiting | Phase 3 | 412 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 24 | Jul 22, 2026 | clinicaltrials |
| NCT07095751 | Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer | not yet recruiting | N/A | 60 | Chinese University of Hong KongOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720921 | Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )(LUXUS0701) | not yet recruiting | Phase 2 | 20 | Peking University First HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07207824 | DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC(HERO) | recruiting | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07307456 | Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration(MARINE-01) | recruiting | Phase 2 | 31 | Changhai HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07717242 | Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer(SYSTEM) | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05531123 | Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer | active not recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05833867 | Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer | recruiting | Phase 1 | 20 | Shilpa Gupta, MDOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07424287 | A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC | recruiting | Phase 3 | 236 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03504163 | Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] | active not recruiting | Phase 2 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT00848289 | Genetic Susceptibility to Bladder Cancer | active not recruiting | — | 6,086 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer | active not recruiting | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04700124 | Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)(KEYNOTE-B15) | active not recruiting | Phase 3 | 808 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Jul 16, 2026 | clinicaltrials |
| NCT05775471 | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer | recruiting | Phase 2 | 21 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05843448 | IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer | active not recruiting | Phase 1 | 6 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06356155 | Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer(NEPTUNE) | recruiting | Phase 2 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03317158 | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder(ADAPT-BLADDER) | active not recruiting | Phase 1 / Phase 2 | 186 | Noah Hahn, M.D.OTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705074 | FAPI PET Imaging - An Exploratory Study(FAPIPET) | not yet recruiting | Phase 1 / Phase 2 | 770 | Martin HuellnerOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT03374267 | Registry Platform Urologic Cancer(CARAT) | recruiting | — | 2,230 | iOMEDICO AGINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06896162 | PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival(PROGRESS) | recruiting | N/A | 500 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05024734 | Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids(GAIN-INST) | active not recruiting | Phase 2 | 31 | Roland Seiler-BlarerOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05644041 | Intravesical Gem/Doce in Patients With NMIBC | active not recruiting | Phase 2 | 31 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT06834204 | Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors(ACCESS-PC) | enrolling by invitation | N/A | 266 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07630155 | Office-Based Ureteroscopy Utilizing a Single Use Digital, Flexible Ureteroscope for Upper Tract Urothelial Carcinoma | recruiting | N/A | 10 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07690878 | PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer | not yet recruiting | Phase 2 | 35 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04564781 | Predicting BCG Response | recruiting | — | 400 | Cedars-Sinai Medical CenterOTHER | 3 | Jul 6, 2026 | clinicaltrials |
| NCT07302230 | Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial(EMPOWER) | recruiting | N/A | 100 | University of WashingtonOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07614594 | Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis | recruiting | — | 800 | Henan Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | active not recruiting | Phase 3 | 367 | CG Oncology, Inc.INDUSTRY | 2 | Jul 1, 2026 | clinicaltrials |
| NCT06101290 | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)(LAYOVER) | recruiting | N/A | 150 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer(INSITE) | recruiting | — | 2,500 | Convergent Genomics, Inc.NETWORK | 2 | Jun 29, 2026 | clinicaltrials |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07321210 | Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)(UTLUND) | recruiting | N/A | 150 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03967977 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | active not recruiting | Phase 3 | 420 | BeiGeneINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2026source: clinicaltrials